中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 10
Oct.  2022
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2022  >  38(10): 2383-2386

Role of bile acids in cirrhosis-related cardiomyopathy

DOI: 10.3969/j.issn.1001-5256.2022.10.035

  • Department of Gastroenterology, Tangdu Hospital, The Air Force Military Medical University, Xi'an 710038, China

Research funding:

National Natural Science Foundation of China (General Project) (81770534)

More Information
  • Corresponding author: WANG Jingjie, jingjiefmmu@163.com(ORCID: 0000-0003-0502-0003)
  • Received Date: 2022-03-08
  • Accepted Date: 2022-04-12
  • Published Date: 2022-10-20
    Abstract
  • Liver cirrhosis-related cardiomyopathy (CCM) is a common and easily overlooked complication associated with liver cirrhosis. Because of the high incidence and impact on success of the liver transplantation and the transcarotid intrahepatic portosystemic shunt surgery, it has attracted the attention of researchers in the field recently. Liver cirrhosis patients have liver morphological alterations, which result in increased serum level of total bile acids and changes in bile acid composition. The increased bile acid concentrations are cardiotoxic and change cardiac functions. This study discussed and summarized recent advancements in the role of bile acids in cirrhosis-related cardiomyopathy in three aspects, i.e., changes in bile acid metabolism in liver cirrhosis patients, effects of bile acid on changes in cardiac functions, and ursodeoxycholic acid as a potential therapeutic agent for CCM. This review expects to provide novel approaches for future prevention and treatment of CCM.

     

    • FullText(HTML)
  • loading
    • References(38)
  • [1]
    IZZY M, VANWAGNER LB, LIN G, et al. Redefining cirrhotic cardiomyopathy for the modern era[J]. Hepatology, 2020, 71(1): 334-345. DOI: 10.1002/hep.30875.
    [2]
    CHAHAL D, LIU H, SHAMATUTU C, et al. Review article: comprehensive analysis of cirrhotic cardiomyopathy[J]. Aliment Pharmacol Ther, 2021, 53(9): 985-998. DOI: 10.1111/apt.16305.
    [3]
    VANWAGNER LB, SERPER M, KANG R, et al. Factors associated with major adverse cardiovascular events after liver transplantation among a national sample[J]. Am J Transplant, 2016, 16(9): 2684-2694. DOI: 10.1111/ajt.13779.
    [4]
    BILLEY C, BILLET S, ROBIC MA, et al. A prospective study identifying predictive factors of cardiac decompensation after transjugular intrahepatic portosystemic shunt: the toulouse algorithm[J]. Hepatology, 2019, 70(6): 1928-1941. DOI: 10.1002/hep.30934.
    [5]
    RIMAL B, PATTERSON AD. Role of bile acids and gut bacteria in healthy ageing of centenarians[J]. Nature, 2021, 599(7885): 380-381. DOI: 10.1038/d41586-021-02196-0.
    [6]
    DESAI MS, MATHUR B, EBLIMIT Z, et al. Bile acid excess induces cardiomyopathy and metabolic dysfunctions in the heart[J]. Hepatology, 2017, 65(1): 189-201. DOI: 10.1002/hep.28890.
    [7]
    DESAI MS, SHABIER Z, TAYLOR M, et al. Hypertrophic cardiomyopathy and dysregulation of cardiac energetics in a mouse model of biliary fibrosis[J]. Hepatology, 2010, 51(6): 2097-2107. DOI: 10.1002/hep.23585.
    [8]
    GINÈS P, KRAG A, ABRALDES JG, et al. Liver cirrhosis[J]. Lancet, 2021, 398(10308): 1359-1376. DOI: 10.1016/s0140-6736(21)01374-x.
    [9]
    Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Gastroenterology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Consensus on the diagnosis and treatment of cholestasis liver diseases(2015)[J]. J Clin Hepatol, 2015, 31(12): 1989-1999. DOI: 10.3969/j.issn.1001-5256.2015.12.005.

    中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会感染病学分会. 胆汁淤积性肝病诊断和治疗共识(2015)[J]. 临床肝胆病杂志, 2015, 31(12): 1989-1999. DOI: 10.3969/j.issn.1001-5256.2015.12.005.
    [10]
    GULAMHUSEIN AF, HIRSCHFIELD GM. Primary biliary cholangitis: pathogenesis and therapeutic opportunities[J]. Nat Rev Gastroenterol Hepatol, 2020, 17(2): 93-110. DOI: 10.1038/s41575-019-0226-7.
    [11]
    CHEN W, WEI Y, XIONG A, et al. Comprehensive analysis of serum and fecal bile acid profiles and interaction with gut microbiota in primary biliary cholangitis[J]. Clin Rev Allergy Immunol, 2020, 58(1): 25-38. DOI: 10.1007/s12016-019-08731-2.
    [12]
    TROTTIER J, BIA EK A, CARON P, et al. Metabolomic profiling of 17 bile acids in serum from patients with primary biliary cirrhosis and primary sclerosing cholangitis: a pilot study[J]. Dig Liver Dis, 2012, 44(4): 303-310. DOI: 10.1016/j.dld.2011.10.025.
    [13]
    YAN LT, LI JF, DUAN ZP, et al. Relationship between bile acid metabolism and chronic non -cholestatic liver disease[J]. Chin J Hepatol, 2018, 26 (2): 151-154. DOI: 10.3760/cma.j.issn.1007-3418.2018.02.016.

    闫力婷, 李俊烽, 段钟平, 等. 胆汁酸代谢与慢性非胆汁淤积性肝脏疾病的关系[J]. 中华肝脏病杂志, 2018, 26(2): 151-154. DOI: 10.3760/cma.j.issn.1007-3418.2018.02.016.
    [14]
    YAN H, ZHONG G, XU G, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus[J]. Elife, 2012, 1: e00049. DOI: 10.7554/eLife.00049.
    [15]
    YAN H, PENG B, LIU Y, et al. Viral entry of hepatitis B and D viruses and bile salts transportation share common molecular determinants on sodium taurocholate cotransporting polypeptide[J]. J Virol, 2014, 88(6): 3273-3284. DOI: 10.1128/JVI.03478-13.
    [16]
    OEHLER N, VOLZ T, BHADRA OD, et al. Binding of hepatitis B virus to its cellular receptor alters the expression profile of genes of bile acid metabolism[J]. Hepatology, 2014, 60(5): 1483-1493. DOI: 10.1002/hep.27159.
    [17]
    MOUZANNAR K, FUSIL F, LACOMBE B, et al. Farnesoid X receptor-α is a proviral host factor for hepatitis B virus that is inhibited by ligands in vitro and in vivo[J]. FASEB J, 2019, 33(2): 2472-2483. DOI: 10.1096/fj.201801181R.
    [18]
    YAN LT, WANG LL, YAO J, et al. Total bile acid-to-cholesterol ratio as a novel noninvasive marker for significant liver fibrosis and cirrhosis in patients with non-cholestatic chronic hepatitis B virus infection[J]. Medicine (Baltimore), 2020, 99(8): e19248. DOI: 10.1097/MD.0000000000019248.
    [19]
    LI JF, YAN LT, YANG YT, et al. Serum total bile acid is closely related to the significant liver injury in patients with non-cholestatic chronic hepatitis B virus infection: a cross-sectional study[J]. Clin Lab, 2020, 66(8): 1591-1600. DOI: 10.7754/Clin.Lab.2020.191258.
    [20]
    SANG C, WANG X, ZHOU K, et al. Bile acid profiles are distinct among patients with different etiologies of chronic liver disease[J]. J Proteome Res, 2021, 20(5): 2340-2351. DOI: 10.1021/acs.jproteome.0c00852.
    [21]
    POWELL EE, WONG VW-S, RINELLA M. Non-alcoholic fatty liver disease[J]. Lancet, 2021, 397(10290): 2212-2224. DOI: 10.1016/S0140-6736(20)32511-3.
    [22]
    NIMER N, CHOUCAIR I, WANG Z, et al. Bile acids profile, histopathological indices and genetic variants for non-alcoholic fatty liver disease progression[J]. Metabolism, 2021, 116: 154457. DOI: 10.1016/j.metabol.2020.154457.
    [23]
    XIAO P, BA TT, DING MM, et al. Advances in clinical research on liver disease during pregnancy[J]. J Clin Hepatol, 2021, 37(5): 1229-1232. DOI: 10.3969/j.issn.1001-5256.2021.05.054.

    肖鹏, 巴桃桃, 丁梦梦, 等. 妊娠期肝病临床研究进展[J]. 临床肝胆病杂志, 2021, 37(5): 1229-1232. DOI: 10.3969/j.issn.1001-5256.2021.05.054.
    [24]
    WILLIAMSON C, GORELIK J, EATON BM, et al. The bile acid taurocholate impairs rat cardiomyocyte function: a proposed mechanism for intra-uterine fetal death in obstetric cholestasis[J]. Clin Sci (Lond), 2001, 100(4): 363-369. DOI: 10.1042/CS20000164
    [25]
    VASAVAN T, DEEPAK S, JAYAWARDANE IA, et al. Fetal cardiac dysfunction in intrahepatic cholestasis of pregnancy is associated with elevated serum bile acid concentrations[J]. J Hepatol, 2021, 74(5): 1087-1096. DOI: 10.1016/j.jhep.2020.11.038.
    [26]
    KEMPLER P, VÁRADI A, KÁDAR E, et al. Autonomic and peripheral neuropathy in primary biliary cirrhosis: evidence of small sensory fibre damage and prolongation of the QT interval[J]. J Hepatol, 1994, 21(6): 1150-1151. DOI: 10.1016/s0168-8278(05)80640-3.
    [27]
    CZUL F, PEYTON A, LEVY C. Primary biliary cirrhosis: therapeutic advances[J]. Clin Liver Dis, 2013, 17(2): 229-242. DOI: 10.1016/j.cld.2012.12.003.
    [28]
    NAM SW, LIU H, WONG JZ, et al. Cardiomyocyte apoptosis contributes to pathogenesis of cirrhotic cardiomyopathy in bile duct- ligated mice[J]. Clin Sci (Lond), 2014, 127(8): 519-526. DOI: 10.1042/CS20130642.
    [29]
    VOIOSU AM, WIESE S, VOIOSU TA, et al. Total bile acid levels are associated with left atrial volume and cardiac output in patients with cirrhosis[J]. Eur J Gastroenterol Hepatol, 2018, 30(4): 392-397. DOI: 10.1097/MEG.0000000000001043.
    [30]
    DESAI MS, EBLIMIT Z, THEVANANTHER S, et al. Cardiomyopathy reverses with recovery of liver injury, cholestasis and cholanemia in mouse model of biliary fibrosis[J]. Liver Int, 2015, 35(4): 1464-1477. DOI: 10.1111/liv.12438.
    [31]
    FIORUCCI S, DISTRUTTI E, CARINO A, et al. Bile acids and their receptors in metabolic disorders[J]. Prog Lipid Res, 2021, 82: 101094. DOI: 10.1016/j.plipres.2021.101094.
    [32]
    PU J, YUAN A, SHAN P, et al. Cardiomyocyte-expressed farnesoid-X-receptor is a novel apoptosis mediator and contributes to myocardial ischaemia/reperfusion injury[J]. Eur Heart J, 2013, 34(24): 1834-1845. DOI: 10.1093/eurheartj/ehs011.
    [33]
    WANG J, ZHANG J, LIN X, et al. DCA-TGR5 signaling activation alleviates inflammatory response and improves cardiac function in myocardial infarction[J]. J Mol Cell Cardiol, 2021, 151: 3-14. DOI: 10.1016/j.yjmcc.2020.10.014.
    [34]
    SHAH RA, KOWDLEY KV. Current and potential treatments for primary biliary cholangitis[J]. Lancet Gastroenterol Hepatol, 2020, 5(3): 306-315. DOI: 10.1016/S2468-1253(19)30343-7.
    [35]
    Chinese Society of Hepatology, Chinese Medical Association. Guidelines on the diagnosis and management of primary sclerosing cholangitis (2021)[J]. J Clin Hepatol, 2022, 38(1): 50-61. DOI: 10.3760/cma.j.cn112138-20211109-00786.

    中华医学会肝病学分会. 原发性硬化性胆管炎诊断及治疗指南(2021)[J]. 临床肝胆病杂志, 2022, 38(1): 50-61. DOI: 10.3760/cma.j.cn112138-20211109-00786.
    [36]
    OVADIA C, SAJOUS J, SEED PT, et al. Ursodeoxycholic acid in intrahepatic cholestasis of pregnancy: a systematic review and individual participant data meta-analysis[J]. Lancet Gastroenterol Hepatol, 2021, 6(7): 547-558. DOI: 10.1016/S2468-1253(21)00074-1.
    [37]
    HANAFI NI, MOHAMED AS, SHEIKH ABDUL KADIR SH, et al. Overview of bile acids signaling and perspective on the signal of ursodeoxycholic acid, the most hydrophilic bile acid, in the heart[J]. Biomolecules, 2018, 8(4): 159. DOI: 10.3390/biom8040159.
    [38]
    MOUSA OY, JURAN BD, MCCAULEY BM, et al. Bile acid profiles in primary sclerosing cholangitis and their ability to predict hepatic decompensation[J]. Hepatology, 2021, 74(1): 281-295. DOI: 10.1002/hep.31652.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (414) PDF downloads(65) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return